Runben Biotechnology Co., Ltd. (SHA:603193)
China · Delayed Price · Currency is CNY 19.65
+0.05 (0.26%)
Sep 15, 2026, 1:05 PM CST
Runben Biotechnology Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,930 | 9,803 | 9,447 | 7,356 | - | - | |
Market Cap Growth | -32.25% | 3.77% | 28.44% | - | - | - |
Enterprise Value | 6,421 | 8,674 | 9,054 | 6,808 | - | - |
Last Close Price | 19.60 | 23.94 | 22.77 | 17.45 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 22.29 | 31.17 | 31.47 | 32.54 | - | - |
Forward PE | 21.08 | 24.66 | 26.27 | 26.80 | - | - |
PS Ratio | 4.66 | 6.35 | 7.17 | 7.12 | - | - |
PB Ratio | 3.39 | 4.41 | 4.54 | 3.83 | - | - |
P/TBV Ratio | 3.52 | 4.60 | 4.66 | 3.87 | - | - |
P/FCF Ratio | 31.91 | 52.31 | 51.62 | 30.79 | - | - |
P/OCF Ratio | 24.00 | 35.62 | 36.73 | 29.13 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.77 | 5.62 | 6.87 | 6.59 | - | - |
EV/EBITDA Ratio | 16.44 | 24.90 | 28.04 | 25.94 | - | - |
EV/EBIT Ratio | 17.43 | 26.46 | 29.87 | 28.06 | - | - |
EV/FCF Ratio | 25.84 | 46.28 | 49.47 | 28.50 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
Debt / EBITDA Ratio | 0.00 | 0.00 | 0.01 | 0.02 | 0.04 | 0.07 |
Debt / FCF Ratio | 0.00 | 0.01 | 0.02 | 0.02 | 0.06 | - |
Net Debt / Equity Ratio | -0.64 | -0.66 | -0.69 | -0.83 | -0.51 | -0.45 |
Net Debt / EBITDA Ratio | -3.88 | -4.21 | -4.43 | -6.09 | -1.89 | -1.82 |
Net Debt / FCF Ratio | -6.07 | -7.83 | -7.82 | -6.69 | -2.96 | 18.84 |
Asset Turnover | 0.70 | 0.68 | 0.62 | 0.73 | 1.16 | 1.26 |
Inventory Turnover | 4.68 | 5.41 | 5.23 | 4.64 | 4.93 | 5.40 |
Quick Ratio | 7.84 | 13.21 | 10.58 | 16.93 | 3.97 | 3.64 |
Current Ratio | 8.74 | 14.53 | 11.63 | 18.04 | 5.28 | 4.56 |
Return on Equity (ROE) | 15.59% | 14.62% | 15.00% | 17.10% | 24.93% | 29.72% |
Return on Assets (ROA) | 9.42% | 8.99% | 8.94% | 10.66% | 15.06% | 17.69% |
Return on Invested Capital (ROIC) | 32.87% | 40.57% | 53.19% | 60.54% | 45.44% | 46.55% |
Return on Capital Employed (ROCE) | 15.70% | 14.70% | 14.60% | 12.60% | 24.30% | 22.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.44% | 3.21% | 3.18% | 3.07% | - | - |
FCF Yield | 3.13% | 1.91% | 1.94% | 3.25% | - | - |
Dividend Yield | 2.20% | 1.92% | 1.80% | 0.97% | - | - |
Payout Ratio | 51.94% | 56.02% | 45.32% | - | 2.15% | 25.65% |
Buyback Yield / Dilution | 1.12% | 0.60% | -14.85% | -3.71% | -1.61% | -9.69% |
Total Shareholder Return | 3.32% | 2.52% | -13.05% | -2.74% | -1.61% | -9.69% |